

# Development and Validation of A HPLC Method for the Determination of Metformin Hydrochloride, Repaglinide and Pioglitazone Hydrochloride in Multicomponent Formulation

Pradip Patil<sup>1</sup>, Pankajkumar Nariya<sup>1</sup>, Mahesh Savant<sup>1\*</sup>

<sup>1</sup> Department of Chemical Sciences, Faculty of Science, Atmiya University, Rajkot ,360005 India.

(Received: 05 January 2026

Revised: 15 February 2026

Accepted: 02 March 2026)

## KEYWORDS

Pioglitazone, Metformin Hydrochloride, Repaglinide, RP-HPLC, Oral Hypoglycemic Agent.

## ABSTRACT:

A simple, rapid, and precise reversed-phase high-performance liquid chromatographic method for simultaneous analysis of Metformin Hydrochloride, Repaglinide and Pioglitazone Hydrochloride in a tablet dosage form has been developed and validated. Chromatography was performed on a 25 cm × 4.6 mm i. d., 5-mm particle, C18 column with 85:15 (v/v) methanol: 20 mM potassium dihydrogen phosphate buffer as mobile phase at a flow rate of 1.2 ml/min. UV detection at 227 nm; Metformin Hydrochloride, Repaglinide, Pioglitazone Hydrochloride were eluted with retention times of 2.15, 3.787, and 4.57 min, respectively. The method was validated in accordance with ICH guidelines. Validation revealed the method is specific, rapid, accurate, precise, reliable, and reproducible. Calibration plots were linear over the concentration ranges 50-250 mg/ml for Metformin Hydrochloride, 3.0-15.0 mg/ml for Repaglinide and 2-10 mg/ml for Pioglitazone Hydrochloride. Limits of detection were 0.20, 0.04, and 0.10 mg/ml and limits of quantification were 0.75, 0.18, and 0.30 mg/ml for Metformin Hydrochloride, Nateglinide, and Pioglitazone Hydrochloride, respectively. The high recovery and low coefficients of variation confirm the suitability of the method for simultaneous analysis of the three drugs in tablets. Statistical analysis proves that the method is suitable for the analysis of Metformin Hydrochloride, Repaglinide and Pioglitazone Hydrochloride as a bulk drug and in pharmaceutical formulation without any interference from the excipients. It may be extended to study the degradation kinetics of three drugs and also for its estimation in plasma and other biological fluids.

## INTRODUCTION

Metformin, [Mt] chemically [1, 1-dimethyl biguanide hydrochloride] (**Figure 1**) [1]. It acts by suppressing excessive hepatic glucose production and improving glucose clearance, its predominant effect is to decrease fasting plasma glucose. It is the most well-known member of the biguanide group, regarded as the main compound in mixed therapies, and is always used in high doses of about 500 or 850 mg. Repaglinide [Rg] is an oral hypoglycaemic agent which lowers the blood glucose level by stimulating the pancreatic b-cells to secrete insulin [2]. Chemically, it is (S)-2-Ethoxy-4-(1-[2-(piperidin-1-yl) phenyl]-3- methyl butyl carbamoyl methyl) benzoic acid (**Figure 2**). Pioglitazone hydrochloride (Pg) is chemically designated as 5-[[4-[2-(5-Ethyl-2-pyridinyl) ethoxy] phenyl] methyl]-2, 4-thiazolidinedione (**Figure 3**). It is a member of the thiazolidinedione group. The combination of Metformin Hydrochloride, Repaglinide and Pioglitazone is used in pharmaceutical preparations. This combination, however, is not present in any official pharmacopoeia. In

this respect, a method for the analysis of this combination is needed. In the scientific literature, analysis of Mt, Rg, and Pg has been reported as individual ingredients and in combination with other compounds. Analytical methods have included estimation of Mt [3-8]. Rg [9-11], Pg individually [12]. And in two component formulations of Pg and Mt have been analyzed in combination by [13-20]. Simultaneous HPLC analysis of Mt with gliclazide [21] in combinations with other drugs have also been reported [22-31]. Because no chromatographic method for simultaneous analysis of Mt, Pg, and Rg in a combined dosage form has yet been reported, it was essential to develop a chromatographic method for simultaneous estimation of all the three drugs in a tablet formulation. The method described is rapid, economical, precise, and accurate and can be used for routine analysis of tablets. It was validated as per ICH norm [32-34].



## Experimental

### Materials and Methods

Pharmaceutical grade working standards Pioglitazone [Pg] (batch no. 2088581), Repaglinide [Rg] (batch no. 2980007), Metformin HCl [Mt] (batch no. 1997418) procured from Novo Nordisk. All chemicals and reagents were of HPLC grade and were purchased from Merck Chemicals, Mumbai, India.

### Instrumentation

The LC system consisted of a pump (model jasco PU1580, intelligent LC pump) with auto injecting facility (AS-1555 sampler) programmed at 20  $\mu$ l capacity per injection was used. The detector consisted of a UV-vis (Jasco UV 1575) model operated at a wavelength of 220 nm. The software used was jasco borwin version 1.5, LC-Net II/ADC system. The column used was HiQ Sil C18HS (250mm $\times$ 4.6 mm, 5.0  $\mu$ m) Kya Technologies Corporation. Different mobile phases were tested in order to find the best conditions for separation of Mt, Rg and Pg. The mobile phase contained methanol: 20 mM potassium dihydrogen phosphate (85:15, v/v) and the flow rate was maintained at 1.2 ml/min UV detection was carried out at 227 nm. The mobile phase and samples was filtered using 0.45  $\mu$ m membrane filter. Mobile phase was degassed by ultrasonic vibrations prior to use. All determinations were performed at ambient temperature.

### Standard Solutions and Calibration Graphs for Chromatographic Measurement

Mt, Rg and Pg were weighed accurately and separately transferred to 10 mL volumetric flasks. All the drugs were dissolved in HPLC-grade methanol to prepare 1000  $\mu$ g/ml standard stock solutions. Calibration standards at five levels were prepared by appropriately mixed and further diluted stock standard solutions in the concentration range of 50-250  $\mu$ g/ml for Mt and 3-15  $\mu$ g/ml for Rg and 2-10  $\mu$ g/ml Pg. Samples in triplicate were made for each concentration and peak areas were plotted against the corresponding concentrations to obtain the calibration graphs.

### Sample Preparation

For the analysis of a tablet dosage form, 20 tablets were weighed individually and their average mass was determined. Then, the tablets were crushed to a fine powder. The powder amount equivalent to 500 mg of Mt,

30 mg of Rg and 15 of Pg were transferred to a 25 mL volumetric flask and dissolved in 25 mL of HPLC-grade methanol, sonication was done for 15 min with swirling. After sonication, the solution was filtered through a Whatman filter paper (#41). Before the assay of tablet formulations, 6 replicate aliquots (each 20 mL in volume) of the appropriately diluted tablet stock solution were sonicated for 15 min, then injected into the chromatographic system, and analyzed quantitatively. The analysis was repeated six times. The possibility of excipient interference with the analysis was examined.

### Optimization of HPLC Method

The HPLC procedure was optimized with a view to develop a simultaneous assay method for Mt, Ng and Rg respectively. The mixed standard stock solution (200  $\mu$ g/ml of Mt, 12  $\mu$ g/ml of Rg, 6  $\mu$ g/ml of Pg) injected in HPLC. Different ratios of methanol and potassium dihydrogen phosphate buffer at different pH and molarities were tried.

### METHOD VALIDATION

The method was validated according to the ICH guidelines [19]. The following validation characteristics were addressed: linearity, accuracy, precision, and specificity, limits of detection and quantitation and robustness.

### Linearity and Range

Linearity of the method was studied by injecting the mixed standard solutions in the concentration range of 50-250  $\mu$ g/ml for Mt and 3-15  $\mu$ g/ml for Rg and 2-10  $\mu$ g/ml Pg injected six times into the LC system keeping the injection volume constant. The peak areas were plotted against the corresponding concentrations to obtain the calibration graphs.

### Precision

The precision of the proposed method was evaluated by carrying out six independent assays of test sample. RSD (%) of six assay values obtained was calculated. Intermediate precision was carried out by analyzing the samples by a different analyst on another instrument.

### Limit of Detection and Quantification

The limit of detection (LOD) and limit of quantitation (LOQ) for the procedure were performed on samples



containing very low concentrations of analytes under the ICH guidelines. By applying the visual evaluation method, LOD was expressed by establishing the minimum level at which the analyte can be reliably detected. LOQ was considered as the lowest concentration of analytes in standards that can be reproducibly measured with acceptable accuracy and precision.

### Robustness and System Suitability

The robustness was studied by evaluating the effect of small but deliberate variations in the chromatographic conditions. The conditions studied were flow rate (altered by  $\pm 0.1$  ml/min), mobile phase composition (methanol  $\pm 5$  ml). These chromatographic variations were evaluated for resolution between Mt, Rg and Pg.

### Solution Stability

To assess the solution stability, three different concentrations of Mt, Rg and Pg (2, 4 and 6  $\mu\text{g/ml}$ ) were prepared from sample solution and kept at room temperature for 8 days. These solutions were compared with freshly prepared standard solutions.

### System Suitability

The system suitability parameters with respect to theoretical plates, tailing factor, repeatability and resolution between Mt, Rg and Pg peaks were defined.

### Specificity

Injections of the extracted placebo were performed to demonstrate the absence of interference with the elution of the Mt, Rg and Pg. For determining selectivity of the method, a powder blend of typical tablet excipients containing lactose monohydrate, mannitol, maize starch, povidone K<sub>30</sub>, citric acid anhydrous granular, sodium citrate, natural lemon and lime flavor and magnesium stearate was prepared and analyzed. All chromatograms were examined to determine if compounds of interest co-eluted with each other or with any additional excipients peaks.

### Accuracy

Accuracy of the method was carried out by applying the method to drug sample (Mt, Rg and Pg combination tablets) to which known amounts of Mt, Rg and Pg standard powder corresponding to 80, 100 and

120% of label claim had been added (standard addition method), mixed and the powder was extracted and analyzed by running chromatograms in optimized mobile phase. These mixtures were analyzed by the proposed method. The experiment was performed in triplicate and recoveries (%), RSD (%) were calculated.

### Analysis of Marketed Formulation

The marketed formulation was assayed as described above. The peak areas were measured at 227 nm, and concentrations in the samples were determined using multilevel calibration developed on the same LC system under the same conditions using linear regression analyzed for Mt, Rg and Pg in the same way as described earlier.

## RESULTS AND DISCUSSION

### Method Development and Optimization

The HPLC procedure was optimized with a view to develop a suitable LC method for the analysis of Mt, Rg and Pg in fixed dose combined dosage form. Initially methanol and water in different ratios were tried. But Mt gave broad peak shape, so water was replaced by potassium dihydrogen buffer (20 mM), and mixture of methanol and potassium dihydrogen phosphate buffer in different ratios were tried. It was found that methanol: potassium dihydrogen phosphate buffer (20 mM) in ratio of 85: 15, v/v gave acceptable retention time (tR 2.15 min for Mt, tR 3.78 min for Rg and tR 4.575 min for Pg), plates, and good resolution for Mt, Rg and Pg at the flow rate of 1.2 ml/min) Illustration 4.

### Validation

#### Linearity

Linearity was evaluated by analysis of working standard solutions of Mt, Rg and Pg of five different concentrations. The range of linearity was from 50-250  $\mu\text{g/ml}$  for Mt and 3-15  $\mu\text{g/ml}$  for Rg and 2-10  $\mu\text{g/ml}$  Pg. The regression data obtained are represented in Table 1. The result shows that within the concentration range mentioned above, there was an excellent correlation between peak area and concentration of each drug.

#### Precision

The results of the repeatability and intermediate precision experiments are shown in Table 2. The



developed method was found to be precise, with RSD values for repeatability and intermediate precision.

### LOD and LOQ

The LOD and LOQ values were found to be 0.03 and 0.09  $\mu\text{g/ml}$  for Rg and 0.22 and 0.67  $\mu\text{g/ml}$  for Mt, and 0.008 and 0.02  $\mu\text{g/ml}$  for Pg.

### Specificity

Injections of the extracted commonly used excipients were performed to demonstrate the absence of interference with the elution of the drugs. These results demonstrate that there was no interference from other materials in the tablet formulation; therefore, confirm the specificity of the method Table 3.

### System Suitability

System suitability parameters such as the number of theoretical plates, HETP and peak tailing are determined. The results obtained are shown in Table 4.

### Robustness of the Method

To ensure the insensitivity of the developed HPLC method to minor changes in the experimental conditions, it is important to demonstrate its robustness. None of the alterations caused a significant change in resolution between Mt, Rg and Pg, peak area, R.S.D., tailing factor and theoretical plates Table 5.

### Solution Stability Studies

Three different concentrations of Mt, Rg and Pg, 2, 4 and 6  $\mu\text{g/ml}$  were prepared from sample solution and stored at room temperature for 8 days. They were then injected into the HPLC system and no additional peak was found in the chromatogram indicating the stability of Mt, Rg and Pg in the solution Table 6.

### Recovery Studies

Good recoveries of the Mt, Rg and Pg were obtained at various added concentrations for the tablets as shown in Table 7.

### Analysis of a Commercial Formulation

Experimental results of the amount of Mt, Rg and Pg in tablets, expressed as a percentage of label claims were in good agreement with the label claims thereby suggesting that there is no interference from any of the excipients

which are normally present in tablets. Fixed dose combination tablets were analyzed using the proposed procedures Illustration 12. The data of summary of validation parameters are listed in Table 8.

### CONCLUSION(s)

The new HPLC method described in this paper provides a simple, convenient and reproducible approach for the simultaneous identification and quantification that can be used to determine Metformin Hydrochloride, Repaglinide, Pioglitazone Hydrochloride in routine quality control.

### Reference(s)

1. Klepser TB, Kelly MW. Metformin hydrochloride: an antihyperglycemic agent. *Am J Health System Pharm* 1997; 54: 893-903.
2. Campbell DB, Lavielle R, Nathan C. The mode of action on clinical pharmacology of gliclazide a review. *Diab Res Clin Pract* 1991; 14: S21–S36.
3. Sane RT, Banavalikar VJ, Bhate VR, Nayak VG. Gas chromatographic determination of metformin hydrochloride from pharmaceutical preparations. *Indian Drugs* 1989; 26(11): 647-648.
4. El-Khateeb S Z, Assaad H N, El-Bardicy M G, Ahmad A S Determination of metformin hydrochloride in tablets by nuclear magnetic resonance spectroscopy. *Anal Chim Acta* 1988; 208(1-2): 321-324.
5. Koseki N, Kawashita H, Niina M, Nagae, Y Masuda N, Development and validation for high selective quantitative determination of metformin in human plasma by cation exchanging with normal-phase LC/MS/MS. *J Pharm Biomed Anal* 2005; 36: 1063-1072.
6. Wang Y, Tang Y, Gu J, Fawcett JP, Bai X, Rapid and sensitive liquid chromatography-tandem mass spectrometric method for the quantitation of metformin in human plasma. *J Chromatogr B* 2004; 808: 215-219.
7. Heinig K, Bucheli F, Fast liquid chromatographic-tandem mass spectrometric (LC–MS–MS) determination of metformin in plasma samples. *J Pharm Biomed Anal* 2004; 34: 1005-1011.



8. Kar M, Choudhury PK, HPLC method for estimation of metformin hydrochloride in formulated microspheres and tablet dosage form. *Indian J Pharm Sci* 2009; 71: 318-320.
9. El Kousy NM. Stability-indicating densitometric determination of some antidiabetic drugs in dosage forms, using TLC. *Mikrochim Acta* 1998; 128: 65-68.
10. The European Pharmacopoeia 2005; I: 1660-1662.
11. Noguchi H, Tomita N, Naruto S. Determination of Gliclazide in serum by High Performance Liquid Chromatography used solid-phase extraction. *J Chromatogr Biomed Appl* 1992; 583: 266-269.
12. Yamashita K, Murakami H, Okuda T, Motohashi M. High-performance liquid chromatographic determination of pioglitazone and its metabolites in human serum and Urine. *J Chrom A* 1996; 677 (1): 141-146.
13. John-Lin Z, Karieger W, JiDD, Shum L, Simultaneous determination of pioglitazone and its two active metabolites in human plasma by L-MS-MS. *J Pharm Biomed Anal* 2003; 33: 101.
14. Kolte BL, Raut BB, Deo AA, Bagoool MA, Shinde DB, Simultaneous High-Performance Liquid Chromatographic Determination of Pioglitazone and Metformin in Pharmaceutical-Dosage Form. *J Chrom Science* 2004; 42: 27-31.
15. Sane RT, Menon SN, Mote M, Gundi G, Simultaneous determination of pioglitazone and glimepiride by high-performance liquid chromatography. *Chromatographia* 2004; 59: 451.
16. Davison G, Beckett AH, Stenlake JB, *Practical Pharmaceutical Chemistry*, CBS Publishers and distributors, New Delhi, 1997.
17. T.C. Lalhariatpulli and N. Kawathekar, *Indian Drugs*. Derivative spectrophotometric estimation of pioglitazone and metformin hydrochloride. 2005; 42(11): 740.
18. Kolte BL, Raut BB, Deo AA, Bagoool MA, Shinde DB. Simultaneous High-Performance Liquid Chromatographic Determination of Pioglitazone and Metformin in Pharmaceutical-Dosage Form. *J Chrom Science* 2004; 42: 27-31.
19. Shankar Madhira B, Modi Vaibhav D, Shah Dimal A, Bhatt Kashyap K, Mehta, Rajendra S, Geetha Madhira. Estimation of Pioglitazone hydrochloride and Metformin hydrochloride in tablets by Derivative Spectrophotometry and Liquid Chromatographic Methods. *J J AOAC International* 2005; 88: 1167-1172.
20. Sahoo PK, Sharma R, Chaturvedi SC, Simultaneous Estimation of Metformin hydrochloride and Pioglitazone hydrochloride by RP-HPLC method from combined tablet dosage form, *Ind J Pharm Sci* 2008; 70: 383-386.
21. Bhanu R, Kulkarni SK, Kadam AB. Simultaneous estimation of gliclazide and metformin in pharmaceutical dosage by reverse phase HPLC. *Indian Drugs*, 2006; 43(1): 16.
22. Aburuz S, Milership J, McElnay J. The development and validation of liquid chromatography method for the simultaneous determination of metformin and glipizide, glicazide, glibenclamide or glimeperide in plasma. *Journal of Chromatography B* 2005; 817: 277-286.
23. Chaturvedi PK, Sharma R. Development and Validation of an RP-HPLC Method for Simultaneous Analysis of a Three-Component Tablet Formulation Containing Metformin Hydrochloride, Pioglitazone Hydrochloride, and Glibenclamide. *Acta Chromatographica* 2008; 20(3): 451-461.
24. Mistri H N, Jangid A G, Shrivastav P S, Liquid chromatography tandem mass spectrometry method for simultaneous determination of antidiabetic drugs metformin and glyburide in human plasma. *J. Pharm. Biomed. Anal.* 2007; 45: 97-106.
25. Georgita C, Albu F, David V, Medvedovici AJ, Simultaneous assay of metformin and glibenclamide in human plasma based on extraction-less sample preparation procedure and LC/(APCI)MS, *J Chromatogr B Analyt Technol Biomed Life Sci* 2007; 854: 211-218.
26. Zhang L, Tian Y, Zhang Z, Chen Y. Simultaneous determination of Metformin and



rosiglitazone in human plasma by liquid chromatography/tandem Mass spectrometry with electrospray ionization: application to a pharmacokinetic study. *J Chromatogr B Analyt Technol Biomed Life Sci* 2007; 854: 91-98.

27. Gupta VD. Quantitation of glipizide and glyburide (glibenclamide) in tablets using high performance liquid chromatography. *J Liq Chromatogr* 1986; 9(16): 3607-3615.
28. Nadkarni DR, Merchant RN, Sundaresan M, Bhagwat AM. Isocratic separation and simultaneous estimation of four anti-diabetic members of the sulphonyl urea family by reverse phase HPLC. *Indian Drugs* 1997; 34(11): 650-653.
29. Aruna A, Nancey K. Simultaneous estimation of glipizide and metformine in solid dosage form by UV-spectrophotometry. *Indian Drugs* 2000; 37(10): 533-536.
30. Duby A, Shukla IC. Microgram determination of glipiozide and metformine HCl in pharmaceutical preparation by HPLC method. *Indian Drugs*. 2002; 39(8): 446-449.
31. Ding CG, Zhou Z, Ge QH, Zhi XJ, Ma LL. Simultaneous determination of metformin and glipizide in human plasma by liquid chromatography-tandem mass spectrometry, *Biomed Chromatogr*. 2007; 21: 132-138.
32. Code Q2 (R1)-Text on Validation of Analytical Procedure Step-3 Consensus Guideline, ICH Harmonised Tripartite Guideline, 2005.
33. Code Q2A-Text on Validation of Analytical Procedure Step-3 Consensus Guideline, ICH Harmonised Tripartite Guideline, 1994.
34. Code Q2B-Validation of Analytical Procedure Methodology Step-4 Consensus Guideline, ICH Harmonised Tripartite Guideline, 1994.




Figure No. 1: Structure of Metformin Hydrochloride




Figure No. 2: Structure of Repaglinide




Figure No. 3: Structure of Pioglitazone Hydrochloride




Figure 3: A Chromatogram of Metformin Hydrochloride, Repaglinide and Pioglitazone Hydrochloride

**Table 1: Linear regression data for the calibration curves <sup>a</sup>**

Compound	Linearity (µg/ml)	y = A + Bx		r <sup>2</sup>
		A	B	
Mt	50-250	94169	97790	0.999
Rg	3-15	6186.x	- 250.0	0.999
Pg	2-10	36611	39561	0.999

<sup>a</sup>n = 6; r<sup>2</sup>, coefficient of correlation**Table 2. Intra and Inter Day Precision of HPLC method <sup>a</sup>**

Compound	Repeatability		Intermediate	
	Mean% assay	% R.S.D.	Mean% assay	% R.S.D.
Mt	101.07	0.27	100.90	0.11
Rg	100.81	1.72	99.15	0.80
Pg	100.05	0.47	99.09	1.38

<sup>a</sup> n = 6, (2, 6, 10 µg/ml for Pg 3, 9, 15 µg/ml for Rg and 10, 30, 50 µg/ml for Mt)**Table 3. Statistical Analysis of Parameters Required For System Suitability Testing of the Proposed HPLC Method**

Parameters	Mt	Rg	Pg
Theoretical plates	39625.65	2390.16	3765.46
Resolution	-	6.43	2.41
Peak asymmetry	1.44	1.34	1.27
% R.S.D.	0.08	0.03	0.06

**Table 4. Robustness Testing <sup>a</sup>**

Chromatographic Factors <sup>a</sup>	Level	Retention time, t <sub>R</sub> (min)			Resolution (Rs)			Asymmetry (As)		
		Mt	Rg	Pg	Mt	Rg	Pg	Mt	Rg	Pg
Flow rate (ml/min)	1.1	2.27	3.93	5.01	0	6.01	2.39	1.15	1.46	1.38
	1.2	2.15	3.78	4.57	0	6.43	2.41	1.04	1.34	1.27
	1.3	2.01	3.70	4.00	0	6.49	2.48	1.01	1.30	1.25
% of methanol	83	2.23	3.98	4.89	0	6.04	2.40	1.19	1.66	1.18
	85	2.15	3.78	4.57	0	6.43	2.41	1.04	1.34	1.27
	88	2.08	3.10	4.13	0	6.67	2.86	1.09	1.50	1.55

<sup>a</sup> n = 6

**Table 5. Stability of drugs in sample solutions <sup>a</sup>**<sup>a</sup> (n = 6) Average of three concentrations (2, 6, 10 µg/ml for Pg 3, 9, 15 µg/ml for Rg and 10, 30, 50 µg/ml for Mt)

Parameters	Mt	Ng	Pg
% R.S.D	0.74	0.04	1.10

**Table 6: Recovery studies <sup>a</sup>**

Label claim	Amount of drug added (%)	Total amount mg	Amount recovered, mg ± % RSD	% Recovery
Pg 15 mg	80	27	26.74 ± 0.09	99.04
	100	30	29.85 ± 0.06	99.51
	120	33	32.88 ± 1.02	99.66
Rg 30 mg	80	54	53.78 ± 1.75	99.61
	100	60	59.94 ± 1.97	99.90
	120	66	66.01 ± 0.08	100.02
Mt 500 mg	80	900	900.18 ± 0.12	100.03
	100	1000	1004 ± 0.11	100.41
	120	1100	1098.24 ± 0.04	99.84

<sup>a</sup> n = 6**Table 7 Applicability of the HPLC method for the analysis of the pharmaceutical formulations**

Sample	Label claim (mg)	Drug Content (%)	% R.S.D.
Pg	15	99.03	0.15
Rg	30	99.19	0.72
Mt	500	99.88	0.08

**Table 8. Summary of Validation Parameters**

Parameter	Mt	Rg	Pg
Linearity range (µg/ml)	50-100	3-15	2-10
Correlation coefficient	0.999 ± 0.09	0.999 ± 0.18	0.999 ± 0.06
Limit of detection (µg/ml)	0.03	0.22	0.008
Limit of quantitation (µg/ml)	0.09	0.67	0.02
Recovery (n = 6)	100.03	99.84	99.40
Precision (% R.S.D.)			
Repeatability	0.27	1.72	
Inter day	0.11	0.80	0.47
			1.38
Robustness	Robust	Robust	Robust